WO2012159593A2 - A combined oral formulation with controlled release of acetylsalicylic acid and a method for the preparation - Google Patents

A combined oral formulation with controlled release of acetylsalicylic acid and a method for the preparation Download PDF

Info

Publication number
WO2012159593A2
WO2012159593A2 PCT/CZ2012/000042 CZ2012000042W WO2012159593A2 WO 2012159593 A2 WO2012159593 A2 WO 2012159593A2 CZ 2012000042 W CZ2012000042 W CZ 2012000042W WO 2012159593 A2 WO2012159593 A2 WO 2012159593A2
Authority
WO
WIPO (PCT)
Prior art keywords
starch
weight
formulation according
granulate
acetylsalicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2012/000042
Other languages
French (fr)
Other versions
WO2012159593A3 (en
WO2012159593A9 (en
Inventor
OIga SAKOVA
Beata Vladovicova
Anna KABZANOVA
Viera Kormanova
Stefan ZORICAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Priority to ROA201300838A priority Critical patent/RO130316A2/en
Priority to UAA201315213A priority patent/UA111743C2/en
Publication of WO2012159593A2 publication Critical patent/WO2012159593A2/en
Publication of WO2012159593A3 publication Critical patent/WO2012159593A3/en
Publication of WO2012159593A9 publication Critical patent/WO2012159593A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention relates to combined oral formulations with controlled release of acetylsalicylic acid, comprising the active ingredient acetylsalicylic acid, at least one another active ingredient from the group of non-narcotic analgesics and/or natural psychotropic agents, and to a method for the preparation thereof.
  • An oral dosage form comprising the active ingredients acetylsalicylic acid, paracetamol and caffeine, and a method for the manufacture thereof is described in international application WO 95/07082 A [EGIS Gyogyszergyar RT, HU].
  • the above-specified tablet comprises the combination of the above-mentioned active ingredients in admixture with pharmaceutical excipients, which are polyvinyl butyral) as a binder and low-substitution hydroxypropyl cellulose as a disintegrant.
  • pharmaceutical excipients which are polyvinyl butyral) as a binder and low-substitution hydroxypropyl cellulose as a disintegrant.
  • the tablets show a satisfactory long-term stability in heavy conditions.
  • the manufacture described is based on wet granulation of a mixture of the active ingredients acetylsalicylic acid, paracetamol and caffeine.
  • the mixture of the active ingredients is fluid sprayed with a 96% ethanolic solution of polyvinyl butyral) with stearic acid in the selected ratio.
  • the prepared granulate is fluid dried until a moisture content of the granulate of 0.5%. (The moisture content of the granulate is measured at the conditions of 70°C/30 minutes.)
  • Low-substitution hydroxypropyl cellulose and stearic acid are admixed to the dried and sieved (mesh size 1 mm) granulate. Tablets are compressed from the prepared mixture.
  • stable oral tablets with controlled release of acetylsalicylic acid comprise at least one further active ingredient selected from the group consisting of non-narcotic analgesics and natural psychotropic agents, and by a specific ratio of the excipients, preferably of starch and stearic acid, wherein the ratio of acetylic acid to the mixture of stearic acid and starch is preferably from 2:1 to 10:1.
  • the further active ingredient from the group of non-narcotic analgesics is paracetamol or ibuprofen, the natural psychotropic agent is caffeine.
  • Suitable starches include corn, potato or rice starch, the corn starch having a moisture content of 3% to 20%, preferably of 11% to 18%.
  • stearic acid having a particle size of 1 to 20 ⁇ is used; preferably, 90% of stearic acid has a particle size of from 1 to 20 ⁇ .
  • the amount of starch in the formulation is from 2% by weight to 10% by weight, preferably from, 4% by weight to 5% by weight, and the amount of stearic acid is from 1% by weight to 5% by weight, preferably from 1.5% by weight to 3% by weight.
  • the combined oral formulation in a preferred embodiment, comprises acetylsalicylic acid in an amount of from 25% to 40% by weight, preferably from 30% to 40% by weight, paracetamol in an amount of from 25% to 40% by weight, preferably from 30% to 40% by weight, and caffeine from 4% to 15% by weight, preferably from 7% to 8 % by weight.
  • the combined oral formulation is prepared by a simple, not demanding, technological process, not requiring any special manufacturing facilities for granulation, without necessity of enhanced safety modifications of the workspace and equipment.
  • stearic acid the substance responsible for the achieved effect, i.e. prolonged release of acetylsalicylic acid and the pharmaceutical excipients starch and lactose used in various premixes, by their mutual weight ratios and by their technological processing, compression into tablets produces the desired release profile of acetylsalicylic acid and a long-term stable product.
  • the oral tablets prepared by the method of the invention, comply with the stability requirement of a formulation comprising a combination of the active ingredients acetylsalicylic acid, at least one further active ingredient from the group of nonnarcotic analgesics and/or natural psychotropic agents, with the desired release profile of acetylsalicylic acid, without the necessity of any further treatment, e.g., by coating the tablets with a film coat.
  • the manufacture of combined oral tablets substantially consists in preparation of premixes of the individual active ingredients.
  • the manufacture of an acetylsalicylic premix in principle comprises simple mixing of acetylcsalicylic acid and the pharmaceutical excipients, stearic acid and starch, in a specific ratio, moisturizing the mixture during mixing, drying, sieving, and final blending until a visually homogeneous mixture is formed.
  • the manufacture of a paracetamol premix in principle comprises simple mixing of paracetamol and the pharmaceutical excipient (preferably corn starch), moisturizing the mixture with a starch paste until formation of the required structure of the granulation material, drying the same and modification of the particle size of the granulate.
  • the pharmaceutical excipient preferably corn starch
  • the manufacture of a caffeine triturate in principle comprises simple mixing of caffeine and the pharmaceutical excipient, preferably lactose, followed by blending the resulting mixture with starch.
  • the pharmaceutical excipient preferably lactose
  • the final tabletting blend is prepared by mixing of the individual active ingredients premixes with addition of a glidant facilitating the flowability of the tabletting blend and formation of pressings having the desired weight, strength and friability, which are chemically and physically stable for a sufficiently long period of time and can be filled into commonly used pharmaceutical packages without any problems.
  • the combined oral formulation with controlled release of acetylsalicylic acid comprises, in addition to the three active ingredients - acetylsalicylic acid, paracetamol and caffeine -, pharmaceutically acceptable excipients, namely:
  • the profile of release of the acetylsalicylic acid active ingredient from a therapeutic composition, prepared according to the present invention can be set up to the requirements by the ratio of stearic acid and starch in the acetylsalicylic premix. Further, it has been surprisingly found that acetylsalicylic acid, which undergoes hydrolysis, can be granulated with purified water without decomposition thereof and, moreover, it has been found that acetylsalicylic acid can be stabilized by mixing with stearic acid.
  • the manufacture of a solid therapeutic formulation according to the present invention substantially consists in mixing, in a high-speed pharmaceutical homogenizer for wet homogenization, paracetamol together with a starch, preferably with a starch having a moisture content of from 3% to 25%, in an amount of from 5% to 20% by weight.
  • the said mixture is gradually moisturized with a starch paste, wherein starch amounts to 10% to 50% by weight of said paste.
  • the mixture is shortly mixed until a granulate is formed.
  • the prepared granulate is dried by the chamber, fluidized, vacuum or microwave radiation method, preferably in fluidized state to obtain a final moisture content between 0.1% and 2.0% by weight. Temperatures of the product during drying should be 35°C to 45°C, preferably 39°C to 41°C.
  • the dried granulate is treated to obtain particle sizes compliant with the tabletting process and homogenized. After complete homogenization the mixture can be used for a tabletting process.
  • a caffeine triturate is admixed to the previously prepared paracetamol granulate, an acetylsalicylic acid granulate and silicon oxide are admixed to the resulting mixture and the final blend is tabletted in rotatory tabletting machines to pressings which have a break resistance of from 20 N to 90 N, preferably from 35 N to 75 N and a disintegration of from 30 seconds to 2 minutes and 30 seconds.
  • the tablets can be of a flat rounded, lens rounded, oval or other shape, with possible presence of a break line or logo on one or both surfaces of the tablet.
  • the thus manufactured tablets can be filled into commonly applicable packages destined for pharmaceutical products, preferably into blister packages constituted by PVC/PVdC combination heat-shapable foil and an aluminum foil coated with an adhesive material.
  • Figure 1 Dissolution profile of acetylsalicylic acid processed in a granulate without stearic acid (acetate buffer pH 4.5; 500 ml; 50 rpm).
  • Figure 2 Dissolution profile of acetylsalicylic acid processed in a granulate with stearic acid (acetate buffer pH 4.5; 500 ml; 50 rpm).
  • Example 1 Tablet composition composition of acetylsalicylic granulate % by weight
  • Acetylsalicylic acid is mixed with corn starch and stearic acid having a particle size up to 100 ⁇ in a pharmaceutical granulator of a suitable type.
  • the resulting mixture is then gradually moisturized with purified water until a granulate forms.
  • the latter is transferred into the receptacle of a fluid dryer and dried under slight fluidization at the temperature of the inlet air of 41°C, until the temperature of the granulate reaches 40°C, which indicates completion of the drying process.
  • the dried granulate is then subjected to sizing through an oscillating screen with mesh of 1.0 mm, followed by homogenizing in a homogenizer.
  • Paracetamol is mixed with corn starch in a pharmaceutical granulator of a suitable type.
  • the resulting mixture is then gradually moisturized with corn paste until a granulate forms.
  • the latter is transferred into the receptacle of a fluid dryer and dried under slight fluidization at the temperature of the inlet air of 55 - 60°C, until the temperature of the granulate reaches 42°C.
  • the dried granulate is then subjected to sizing through an oscillating screen with mesh of 1.25 mm and, subsequently, it is transferred into the receptacle of a fluid dryer and dried until the moisture content of the granulate reaches 1.5 %, measured at 90°C/30 minutes.
  • Caffeine is mixed with lactose in a low-speed homogenizer of a suitable type.
  • the triturate is subjected to sizing through an oscillating screen with mesh of 0.8 mm. Corn starch is added to the sieved triturate.
  • the required amounts of the premixes of the individual active ingredients are homogenized in a low-speed homogenizer by dry homogenization with addition of a glidant, which is silicon oxide.
  • composition is prepared for tabletting in rotatory tabletting machines to pressings containing the desired three active ingredients, having satisfactory content uniformity of caffeine, break resistance and disintegration.
  • the following table shows the values of free salicylic acid, measured during storage in various stress conditions. Free salicylic acid is formed as a degradation product of acetylsalicylic acid by the action of hydrolysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A combined oral solid pharmaceutical formulation with controlled release of acetylsalicylic acid, which comprises at least one further active ingredient selected from the group of non-narcotic analgesics and/or natural psychotropic agents, and stearic acid and starch as excipients in a specific ratio, and a method for the preparation thereof.

Description

A combined oral formulation with controlled release of acetylsalicylic acid and a method for the preparation
Technical Field
The invention relates to combined oral formulations with controlled release of acetylsalicylic acid, comprising the active ingredient acetylsalicylic acid, at least one another active ingredient from the group of non-narcotic analgesics and/or natural psychotropic agents, and to a method for the preparation thereof.
Background Art
An oral dosage form, comprising the active ingredients acetylsalicylic acid, paracetamol and caffeine, and a method for the manufacture thereof is described in international application WO 95/07082 A [EGIS Gyogyszergyar RT, HU].
The above-specified tablet comprises the combination of the above-mentioned active ingredients in admixture with pharmaceutical excipients, which are polyvinyl butyral) as a binder and low-substitution hydroxypropyl cellulose as a disintegrant. The tablets show a satisfactory long-term stability in heavy conditions.
The manufacture described is based on wet granulation of a mixture of the active ingredients acetylsalicylic acid, paracetamol and caffeine. The mixture of the active ingredients is fluid sprayed with a 96% ethanolic solution of polyvinyl butyral) with stearic acid in the selected ratio. The prepared granulate is fluid dried until a moisture content of the granulate of 0.5%. (The moisture content of the granulate is measured at the conditions of 70°C/30 minutes.) Low-substitution hydroxypropyl cellulose and stearic acid are admixed to the dried and sieved (mesh size 1 mm) granulate. Tablets are compressed from the prepared mixture.
The use of the non-pharmacopeia excipient, polyvinyl butyral), which is commonly used in the manufacture of glass and plastic materials, is a major drawback of the subject- matter of the above-described patent application. Further drawbacks include the necessity of using the organic solvent (96% ethanol, a flammable liquid); the technology requiring enhanced safety adaptations of the working space and modifications of the manufacturing equipment. Disclosure of Invention
The above-described drawbacks have been solved by the present invention, in which stable oral tablets with controlled release of acetylsalicylic acid comprise at least one further active ingredient selected from the group consisting of non-narcotic analgesics and natural psychotropic agents, and by a specific ratio of the excipients, preferably of starch and stearic acid, wherein the ratio of acetylic acid to the mixture of stearic acid and starch is preferably from 2:1 to 10:1.
The further active ingredient from the group of non-narcotic analgesics is paracetamol or ibuprofen, the natural psychotropic agent is caffeine.
Suitable starches include corn, potato or rice starch, the corn starch having a moisture content of 3% to 20%, preferably of 11% to 18%. In a preferred embodiment, stearic acid having a particle size of 1 to 20 μιη is used; preferably, 90% of stearic acid has a particle size of from 1 to 20 μιη. The amount of starch in the formulation is from 2% by weight to 10% by weight, preferably from, 4% by weight to 5% by weight, and the amount of stearic acid is from 1% by weight to 5% by weight, preferably from 1.5% by weight to 3% by weight.
The combined oral formulation, in a preferred embodiment, comprises acetylsalicylic acid in an amount of from 25% to 40% by weight, preferably from 30% to 40% by weight, paracetamol in an amount of from 25% to 40% by weight, preferably from 30% to 40% by weight, and caffeine from 4% to 15% by weight, preferably from 7% to 8 % by weight.
The combined oral formulation is prepared by a simple, not demanding, technological process, not requiring any special manufacturing facilities for granulation, without necessity of enhanced safety modifications of the workspace and equipment.
By the use of stearic acid, the substance responsible for the achieved effect, i.e. prolonged release of acetylsalicylic acid and the pharmaceutical excipients starch and lactose used in various premixes, by their mutual weight ratios and by their technological processing, compression into tablets produces the desired release profile of acetylsalicylic acid and a long-term stable product. The oral tablets, prepared by the method of the invention, comply with the stability requirement of a formulation comprising a combination of the active ingredients acetylsalicylic acid, at least one further active ingredient from the group of nonnarcotic analgesics and/or natural psychotropic agents, with the desired release profile of acetylsalicylic acid, without the necessity of any further treatment, e.g., by coating the tablets with a film coat.
The manufacture of combined oral tablets substantially consists in preparation of premixes of the individual active ingredients. The manufacture of an acetylsalicylic premix in principle comprises simple mixing of acetylcsalicylic acid and the pharmaceutical excipients, stearic acid and starch, in a specific ratio, moisturizing the mixture during mixing, drying, sieving, and final blending until a visually homogeneous mixture is formed.
The manufacture of a paracetamol premix in principle comprises simple mixing of paracetamol and the pharmaceutical excipient (preferably corn starch), moisturizing the mixture with a starch paste until formation of the required structure of the granulation material, drying the same and modification of the particle size of the granulate.
The manufacture of a caffeine triturate in principle comprises simple mixing of caffeine and the pharmaceutical excipient, preferably lactose, followed by blending the resulting mixture with starch.
The final tabletting blend is prepared by mixing of the individual active ingredients premixes with addition of a glidant facilitating the flowability of the tabletting blend and formation of pressings having the desired weight, strength and friability, which are chemically and physically stable for a sufficiently long period of time and can be filled into commonly used pharmaceutical packages without any problems.
The combined oral formulation with controlled release of acetylsalicylic acid according to a preferred embodiment of the present invention comprises, in addition to the three active ingredients - acetylsalicylic acid, paracetamol and caffeine -, pharmaceutically acceptable excipients, namely:
a) stearic acid;
b) corn starch;
c) lactose.
It has been surprisingly found and confirmed that the profile of release of the acetylsalicylic acid active ingredient from a therapeutic composition, prepared according to the present invention, can be set up to the requirements by the ratio of stearic acid and starch in the acetylsalicylic premix. Further, it has been surprisingly found that acetylsalicylic acid, which undergoes hydrolysis, can be granulated with purified water without decomposition thereof and, moreover, it has been found that acetylsalicylic acid can be stabilized by mixing with stearic acid.
The manufacture of a solid therapeutic formulation according to the present invention substantially consists in mixing, in a high-speed pharmaceutical homogenizer for wet homogenization, paracetamol together with a starch, preferably with a starch having a moisture content of from 3% to 25%, in an amount of from 5% to 20% by weight. The said mixture is gradually moisturized with a starch paste, wherein starch amounts to 10% to 50% by weight of said paste. The mixture is shortly mixed until a granulate is formed. The prepared granulate is dried by the chamber, fluidized, vacuum or microwave radiation method, preferably in fluidized state to obtain a final moisture content between 0.1% and 2.0% by weight. Temperatures of the product during drying should be 35°C to 45°C, preferably 39°C to 41°C. The dried granulate is treated to obtain particle sizes compliant with the tabletting process and homogenized. After complete homogenization the mixture can be used for a tabletting process. A caffeine triturate is admixed to the previously prepared paracetamol granulate, an acetylsalicylic acid granulate and silicon oxide are admixed to the resulting mixture and the final blend is tabletted in rotatory tabletting machines to pressings which have a break resistance of from 20 N to 90 N, preferably from 35 N to 75 N and a disintegration of from 30 seconds to 2 minutes and 30 seconds.
The tablets can be of a flat rounded, lens rounded, oval or other shape, with possible presence of a break line or logo on one or both surfaces of the tablet.
The thus manufactured tablets can be filled into commonly applicable packages destined for pharmaceutical products, preferably into blister packages constituted by PVC/PVdC combination heat-shapable foil and an aluminum foil coated with an adhesive material.
Brief Description of Drawings Results of a dissolution test (acetate buffer pH 4.5; 500 ml; 50 rpm):
Figure 1: Dissolution profile of acetylsalicylic acid processed in a granulate without stearic acid (acetate buffer pH 4.5; 500 ml; 50 rpm).
Figure 2: Dissolution profile of acetylsalicylic acid processed in a granulate with stearic acid (acetate buffer pH 4.5; 500 ml; 50 rpm).
Examples
The invention is illustrated in the following example, without being limited thereby in any manner.
Example 1 a) Tablet composition composition of acetylsalicylic granulate % by weight
acetylsalicylic acid 37.30 corn starch 4.66
stearic acid 2.94
composition of paracetamol granulate % by weight
paracetamol 37.30
corn starch 4.71
composition of caffeine triturate % by weight
caffeine 7.46
lactose 3.26
corn starch 2.24
excipients % by weight
silicon oxide 0.096
purified water q. s.
b) Preparation method
Acetylsalicylic acid is mixed with corn starch and stearic acid having a particle size up to 100 μηη in a pharmaceutical granulator of a suitable type. The resulting mixture is then gradually moisturized with purified water until a granulate forms. The latter is transferred into the receptacle of a fluid dryer and dried under slight fluidization at the temperature of the inlet air of 41°C, until the temperature of the granulate reaches 40°C, which indicates completion of the drying process. The dried granulate is then subjected to sizing through an oscillating screen with mesh of 1.0 mm, followed by homogenizing in a homogenizer. Paracetamol is mixed with corn starch in a pharmaceutical granulator of a suitable type. The resulting mixture is then gradually moisturized with corn paste until a granulate forms. The latter is transferred into the receptacle of a fluid dryer and dried under slight fluidization at the temperature of the inlet air of 55 - 60°C, until the temperature of the granulate reaches 42°C. The dried granulate is then subjected to sizing through an oscillating screen with mesh of 1.25 mm and, subsequently, it is transferred into the receptacle of a fluid dryer and dried until the moisture content of the granulate reaches 1.5 %, measured at 90°C/30 minutes. Caffeine is mixed with lactose in a low-speed homogenizer of a suitable type. The triturate is subjected to sizing through an oscillating screen with mesh of 0.8 mm. Corn starch is added to the sieved triturate.
The required amounts of the premixes of the individual active ingredients are homogenized in a low-speed homogenizer by dry homogenization with addition of a glidant, which is silicon oxide.
In this manner the composition is prepared for tabletting in rotatory tabletting machines to pressings containing the desired three active ingredients, having satisfactory content uniformity of caffeine, break resistance and disintegration. c) Results of a stability test:
The following table shows the values of free salicylic acid, measured during storage in various stress conditions. Free salicylic acid is formed as a degradation product of acetylsalicylic acid by the action of hydrolysis.
Storage time Salicylic acid
Start 0.06%
Storage conditions 25°C ± 2°C; RH 60% ± 5%
3 months 0.09%
18 months 0.24%
Storage conditions 30°C ± 2"C; RH 65% ± 5%
3 months 0.12%
12 months 0.42%
Storage conditions 40°C ± 2°C; RH 75% ± 5%
3 months 0.75%
6 months 1.98%

Claims

A combined oral formulation with controlled release of acetylsalicylic acid, characterized in that the formulation comprises at least one further active ingredient selected from the group consisting of non-narcotic analgesics and natural psychotropic agents, and the excipients starch and stearic acid.
The formulation according to claim 1, characterized in that the non-narcotic analgesic is paracetamol and/or ibuprofen.
The formulation according to claims 1 or 2, characterized in that natural psychotropic agent is caffeine.
The formulation according to any one of claims 1-3, characterized in that it comprises acetylsalicylic acid and a mixture of stearic acid and starch in a ratio of from 2:1 to 10:1.
The formulation according to any one of claims 1-4, characterized in that it comprises stearic acid in an amount of from 1% to 5% by weight, preferably from 1.5% to 3% by weight, and starch in an amount of from 2% to 10% by weight, preferably from 4% to 5% by weight.
The formulation according to any one of claims 1-5, characterized in that the particle size of stearic acid is in the range of from 1 to 100 μητι.
The formulation according to claim 6, characterized in that up to 90% of stearic acid has a particle size of from 1 to 20 μηι.
The formulation according to any one of claims 1-7, characterized in that the starch is corn starch, potato starch and/or rice starch. The formulation according to claim 8, characterized in that the starch is corn starch.
The formulation according to claim 9, characterized in that the starch is corn starch with a moisture content of from 3% to 20%, preferably from 11% to 18%.
The formulation according to any one of claims 1 to 10, characterized in that the final blend comprises acetylsalicylic acid and paracetamol.
The formulation according to claim 11, characterized in that the final blend comprises acetylsalicylic acid and paracetamol in separate granules.
The formulation according to claim 12, characterized in that the acetylsalicylic acid granulate comprises starch and stearic acid as excipients in a mutual ratio of about 1.58 : 1.
The formulation according to claim 12, characterized in that the paracetamol granulate comprises starch as an excipient.
The formulation according to any one of claims 1-14, characterized in that the final blend comprises a third active ingredient, which is caffeine, in the form of a triturate.
The formulation according to claim 15, characterized in that the caffeine triturate comprises lactose and starch as excipients in a mutual ratio of about 1.46 : 1.
The formulation according to claim 15, characterized in that it comprises acetylsalicylic acid at from 25% to 40% by weight, preferably from 30% to 40% by weight, paracetamol at from 25% to 40% by weight, preferably from 30% to 40% by weight, and caffeine at from 4% to 15% by weight, preferably from 7% to 8% by weight. A method for the preparation of a combined oral formulation with controlled release of acetylsalicylic acid according to any one of claims 1-17, characterized in that a caffeine triturate is admixed to a previously prepared paracetamol granulate, an acetylsalicylic acid granulate and silicon oxide are admixed to the resulting mixture and the final blend is tabletted to pressings which have a break resistance of from 20 N to 90 N, preferably from 35 N to 75 N, and a disintegration of from 30 seconds to 2 minutes and 30 seconds.
The method according to claim 18, characterized in that the acetylsalicylic acid granulate is prepared by mixing acetylsalicylic acid in an admixture with stearic acid and starch, the mixture being moisturized with purified water during mixing, thus forming a granulate.
20. The method according to claim 18, characterized in that the paracetamol granulate is prepared by mixing paracetamol with starch, the mixture being moisturized with starch paste during mixing, thus forming a granulate. 21. The method according to claims 19 or 20, characterized in that the acetysalicylic acid and paracetamol granulates are individually dried by the chamber, vacuum fluidized, or microwave radiation method to obtain a residual moisture content between 0.1% and 2.0% by weight, preferably from 0.5% to 1,5% by weight.
The method according to claim 19, characterized in that the acetylsalicylic granulate dried at a temperature of from 35°C to 45°C, preferably from 39°C to 41°C.
23. The method according to claim 18, characterized in that the caffeine triturate is prepared by mixing caffeine in a mixture with lactose and starch.
PCT/CZ2012/000042 2011-05-25 2012-05-24 A combined oral formulation with controlled release of acetylsalicylic acid and a method for the preparation Ceased WO2012159593A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ROA201300838A RO130316A2 (en) 2011-05-25 2012-05-24 Combined oral formulation for controlled release of acetylsalicylic acid and process for preparing the same
UAA201315213A UA111743C2 (en) 2011-05-25 2012-05-24 Combined oral composition with controlled release of acetylsalicylic acid and method of preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SK5028-2011A SK50282011A3 (en) 2011-05-25 2011-05-25 Controlled acetylsalicylic acid release combined peroral preparation and method for the production thereof
SKPP5028-2011 2011-05-25

Publications (3)

Publication Number Publication Date
WO2012159593A2 true WO2012159593A2 (en) 2012-11-29
WO2012159593A3 WO2012159593A3 (en) 2013-01-17
WO2012159593A9 WO2012159593A9 (en) 2013-03-07

Family

ID=46513601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2012/000042 Ceased WO2012159593A2 (en) 2011-05-25 2012-05-24 A combined oral formulation with controlled release of acetylsalicylic acid and a method for the preparation

Country Status (5)

Country Link
CZ (1) CZ20131028A3 (en)
RO (1) RO130316A2 (en)
SK (1) SK50282011A3 (en)
UA (1) UA111743C2 (en)
WO (1) WO2012159593A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007082A1 (en) 1993-09-10 1995-03-16 EGIS Gyógyszergyár Rt. A combination tablet comprising acetylsalicylic acid and a process for the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239506A (en) * 1964-10-16 1966-03-08 Eastman Kodak Co 3-azabicyclo[3.2.2]nonane sulfonamide compounds
US4505862A (en) * 1981-04-14 1985-03-19 Bristol-Myers Company Diphenydramine dihydrogencitrate
KR100955669B1 (en) * 2007-08-13 2010-05-06 한올바이오파마주식회사 Combination preparations containing HMBCCA reductase inhibitors and aspirin and preparation methods thereof
US20110268798A1 (en) * 2009-01-16 2011-11-03 Add Advanced Drug Delivery Technologies Ltd Orally disntegrating tablets for the treatment of pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007082A1 (en) 1993-09-10 1995-03-16 EGIS Gyógyszergyár Rt. A combination tablet comprising acetylsalicylic acid and a process for the preparation thereof

Also Published As

Publication number Publication date
WO2012159593A3 (en) 2013-01-17
SK50282011A3 (en) 2013-02-04
WO2012159593A9 (en) 2013-03-07
RO130316A2 (en) 2015-06-30
CZ20131028A3 (en) 2014-01-29
UA111743C2 (en) 2016-06-10

Similar Documents

Publication Publication Date Title
JP6014044B2 (en) Rapidly dispersible granules, orally disintegrating tablets, and methods
JP5651818B2 (en) Controlled release formulation to prevent misuse
KR20100087011A (en) Matrix-type pharmaceutical solid preparation
RS53087B (en) SOLID PHARMACEUTICAL COMPOSITIONS OF PERMANENT COMPOSITION CONTAINING IRBESARTAN AND AMLODIPINE, THEIR PREPARATION AND THERAPY USE
CN103610658B (en) Immunomodulator slow-release preparation and preparation method thereof
CN103908456A (en) Disoproxil fumarate, lamivudine and efavirenz tri-combination compound mini-pill tablet and preparation method thereof
EP2902015B1 (en) Preparation method of agomelatine solid preparation
PL236001B1 (en) Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition,
TW200906397A (en) Process for preparing pramipexole dihydrochloride tablets
CN114146089B (en) Pharmaceutical composition containing efavirenz, tenofovir and emtricitabine
JP2011246428A (en) Orally disintegrating medicine and production method
WO2017093890A1 (en) Clobazam tablet formulation and process for its preparation
WO2012159593A2 (en) A combined oral formulation with controlled release of acetylsalicylic acid and a method for the preparation
EP3256105B1 (en) Method of producing a granulated composition
JP5755382B2 (en) Orally disintegrating tablets
JP2015071556A (en) Tablet and production method thereof
JP6440317B2 (en) Oral solid tablets
KR102627892B1 (en) Rapid release drug formulation of anticoagulant and method for manufacturing same
JP2021167306A (en) Method for producing disintegrating particles
JP7109255B2 (en) Method for producing pulverized material and method for producing tablet
SK6002Y1 (en) Combined peroral controlled-release formulation of acetylsalicylic acid
JP2003095980A (en) Composition containing deliquescent substance
JP2007008872A (en) Method for producing granulated particles, granulated particles thereof, and solid preparation
CN103989643A (en) Tablet containing ramelteon and copovidone
JP6407085B2 (en) Tablet and production method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12735186

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013 201300838

Country of ref document: RO

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PV2013-1028

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: A201315213

Country of ref document: UA

122 Ep: pct application non-entry in european phase

Ref document number: 12735186

Country of ref document: EP

Kind code of ref document: A2